ProQR Therapeutics NV (PRQR) - Multiplikator Forward P/S
The implementation of robotic RNA oligonucleotide synthesis systems automates precision molecule screening. The forward P/S ratio demonstrates the impact of liquidity on capitalization, with the value holding around 9.00. ProQR Therapeutics N.V. (PRQR) maintains high authority in ophthalmology, offering hope to patients with rare pathologies, while an inclusive culture and RSU plans help retain leading molecular biologists.
Rincian metrik lan analitis perusahaan proqr.com (PRQR)
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Rasio Total Utang marang Ekuitas ProQR Therapeutics N.V.|PRQR - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas ProQR Therapeutics|PRQR - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku PRQR|PRQR - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan ProQR Therapeutics N.V.|Likuiditas cepet proqr.com
- data bathi bisnis lan rasio investasi:
PRQR - Asil keuangan resik|Bathi mangsa ngarep ProQR Therapeutics N.V.|PRQR - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep ProQR Therapeutics|PRQR - Rasio P/E diaturake wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan PRQR|PRQR - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan ProQR Therapeutics N.V.|PRQR - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan proqr.com|PRQR - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep ProQR Therapeutics N.V.
- informasi babagan volume dodolan lan pendapatan:
Analisis umum perusahaan:ProQR Therapeutics NV PRQR
The forward P/S ratio measures an asset's market value relative to expected revenues, providing a real-time assessment of investors' willingness to pay a premium for future growth. By analyzing the expected price-to-sales ratio, one can determine the risk of overvaluation: for ProQR Therapeutics N.V. (PRQR), unique RNA editing patents and alliances with pharma behemoths justify a high premium, offsetting the pressure of current competition on market capitalization.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|Rega forward marang dodolan QGEN|Ionis Pharma - Multiplikator Forward P/S|RGEN - Multiplikator Forward P/S|Avidity Biosciences (RNA) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan CRSP (crisprtx.com)|WGS (GeneDx) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ultragenyx Pharmaceutical Inc. RARE|Multiplikator forward rega marang pendapatan BEAM (Beam Therapeutics Corp)|Multiplikator Forward P/S Sarepta Corp (SRPT)|Twist Bioscience - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake TXG (10xgenomics.com)|Intellia Therapeutics, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Stoke Therapeutics Inc STOK|BLFS: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Wave Pharma|Rasio rega marang prakiraan pendapatan Maze Therapeutics Inc|sionnatx.com (SION) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan PRME (Prime Medicine)|TSHA (Taysha Gene Therapies Inc) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan uniQure Corp QURE|MGTX: Kapitalisasi marang prakiraan pendapatan|RGNX: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake solidbio.com SLDB|OCGN (Ocugen) - Multiplikator forward rega marang pendapatan|PACB (Pacific Biosciences of California, Inc.) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan BNTC|Design Corp (DSGN) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Rocket Pharmaceuticals (RCKT)|FDMT: Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Lexeo Therapeutics, Inc. LXEO|Rega forward marang dodolan KRRO|EDIT - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan Silence Therapeutics Corp (SLN)|codexis.com (CDXS) - Rasio rega marang prakiraan pendapatan|sangamo.com - Rega forward marang dodolan|NAUT (Nautilus Biotechnology, Inc.) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan MGX (Metagenomi Inc.)|Rasio rega marang prakiraan pendapatan Precision BioSciences, Inc. (DTIL)|generationbio.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S BOLD (Boundless Bio, Inc.)|Multiplikator Forward P/S Exicure Inc. XCUR|IMNN - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan PHIO|mustangbio.com (MBIO) - Rasio rega marang prakiraan pendapatan|TransCode Therapeutics, Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Bionano Genomics Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep adnas.com APDN|Rasio rega marang prakiraan pendapatan bluebird bio (BLUE)|immunoprecise.com (IPA) - Prakiraan rega marang pendapatan|Rasio rega marang prakiraan pendapatan Omega OMGA|Rega forward marang dodolan OMIC|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (syros.com)|TBIO (Telesis Bio) - Multiplikator forward rega marang pendapatan|TCON: Rasio rega marang pendapatan sing dikarepake|UBX (Unity Bio) - Multiplikator Forward P/S
